COMIRNATY is the lead candidate of the Pfizer/BioNTech BNT162 program, which includes another modRNA candidate that encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen antigen; a uridine containing mRNA (uRNA) candidate; and a candidate using self-amplifying mRNA (saRNA).
→ Mazeway:
Mazeway 在 PTT 的推發文記錄 - 2021年 - Disp BBS
Re: [新聞] 爆4死!高端現停打聲浪 專家怒:你們最愛的BNT若死亡是否全下架 - 看板Gossip...